Expression, preparation, uses, and sequence of recombinantly-derived soluble hla-g
CA 2425186 A1 · Owner: University Of Kansas Medical Center · Inventors: Petroff, Margaret G.; Hunt, Joan S.; Morales, Pedro J.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Methods of producing and using recombinant soluble HLA-G are provided. This recombinant soluble HLA-G alters immune responses to tissues organs, fetuses, and embryos which are genetically distinct from the organism receiving or possessing such antigenic material. Preferably forms of this protein include sequences having at least 70 % sequence homology with naturally occurring forms of HLA-G. Specifically, each recombinant form of HLA-G produced and used by the present methods must include a sequence having at least 70 % sequence homology to introm 4 expressed by the HLA-G gene and at least one sequence having at least 70 % sequence homology to one of the .alpha. domains expressed by …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed September 17, 2001. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended September 17, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by September 17, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.